AstraZeneca is a global, science-driven biopharmaceutical company dedicated to discovering, developing, and delivering innovative, meaningful medicines and healthcare solutions that enrich the lives of patients. The vision of AstraZeneca Oncology is to redefine cancer, redefine our solutions to cancer, and restore patients' lives. The Early Data Science team collaborates with our oncology drug project teams throughout the research and early development pipeline, from new target discovery to translational medicine and clinical trials. Our general group aligns its activities to AstraZeneca’s primary areas of focus in Oncology: immuno-oncology, DNA damage response, tumour drivers & resistance, epigenetics, cell therapies, and antibody-drug conjugates.

Excitingly, the team is growing to meet the challenges of pre‑clinical and clinical big data generation initiatives in AZ Oncology, including DNA sequencing, single‑cell and bulk expression, proteomics, and CRISPR. There exists ...